Some lipid drugs lowered lipoprotein(a), but cardiovascular benefit remains uncertain
Several drug classes reduced this blood marker in adult trials. Whether those reductions improve cardiovascular outcomes remains unresolved.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
In adult placebo-controlled trials, some lipid-lowering drugs reduced lipoprotein(a), a blood marker linked to cardiovascular risk. Other drug classes showed no detected change in this marker. The review did not establish whether these reductions produce meaningful cardiovascular benefits, so the findings describe blood levels rather than proven improvements in heart health.
This abstract-based summary concerns a blood marker, with clinical benefits unresolved. Separate placebo comparisons do not establish superiority between drug classes.
What researchers found
Blood lipoprotein(a) concentration
Treatment minus placebo mean difference: −6.37 mg/dL (95% confidence interval −7.26 to −5.47 mg/dL). Trials lasted more than 3 weeks; exact assessment timing is unreported.
Which classes lowered levels
Reductions were reported for PCSK9 monoclonal antibodies, inclisiran, CETP inhibitors and niacin. Higher starting levels accompanied larger absolute reductions for some classes, but this does not establish greater clinical benefit.
Other classes showed no detected change
Statins, bempedoic acid, ezetimibe, omega-3 fatty acids and fibrates showed no detected change in lipoprotein(a). That finding concerns this marker; it does not establish their other effects or prove an exact absence of change.
The original publication
Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
Xie S, Galimberti F, Olmastroni E et al.
Atherosclerosis · 2025
- PubMed ID
- 40618457
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.